

Emilio Sacco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9403041/publications.pdf>

Version: 2024-02-01

88
papers

1,910
citations

304368

22
h-index

301761

39
g-index

108
all docs

108
docs citations

108
times ranked

2194
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. <i>BJU International</i> , 2006, 97, 1234-1241.	1.3	294
2	Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial. <i>BJU International</i> , 2012, 110, 1004-1010.	1.3	103
3	Mirabegron: a review of recent data and its prospects in the management of overactive bladder. <i>Therapeutic Advances in Urology</i> , 2012, 4, 315-324.	0.9	98
4	Value of Current Chemotherapy and Surgery in Advanced and Metastatic Bladder Cancer. <i>Urologia Internationalis</i> , 2012, 88, 249-258.	0.6	80
5	Paraneoplastic Syndromes in Patients with Urological Malignancies. <i>Urologia Internationalis</i> , 2009, 83, 1-11.	0.6	78
6	Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. <i>BJU International</i> , 2007, 100, 274-280.	1.3	62
7	Imaging in Prostate Cancer Diagnosis: Present Role and Future Perspectives. <i>Urologia Internationalis</i> , 2011, 86, 373-382.	0.6	56
8	Imaging in Prostate Cancer Staging: Present Role and Future Perspectives. <i>Urologia Internationalis</i> , 2012, 88, 125-136.	0.6	54
9	ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk BCG failure non muscle invasive bladder cancer: 3-years follow-up outcomes. <i>BMC Cancer</i> , 2018, 18, 1224.	1.1	51
10	Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 433-448.	2.5	49
11	Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis. <i>BJU International</i> , 2007, 99, 1007-1012.	1.3	46
12	Clinical and Pathological Characteristics of Patients Presenting with Biochemical Progression after Radical Retropubic Prostatectomy for Pathologically Organ-Confined Prostate Cancer. <i>Urologia Internationalis</i> , 2006, 76, 202-208.	0.6	37
13	The new surgical robotic platform HUGO TM RAS: System description and docking settings for robot-assisted radical prostatectomy. <i>Urologia</i> , 2022, 89, 603-609.	0.3	35
14	Complications of Extracorporeal Shock Wave Lithotripsy for Urinary Stones: To Know and to Manage Them? A Review. <i>Scientific World Journal</i> , The, 2012, 2012, 1-6.	0.8	31
15	Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. <i>BJU International</i> , 2012, 110, E837-44.	1.3	31
16	Sexual outcomes after organ potency-sparing surgery and glans reconstruction in patients with penile carcinoma. <i>Indian Journal of Urology</i> , 2013, 29, 119.	0.2	31
17	Familial and Hereditary Prostate Cancer by Definition in an Italian Surgical Series: Clinical Features and Outcome. <i>European Urology</i> , 2005, 47, 761-768.	0.9	28
18	Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances. <i>Urologia Internationalis</i> , 2011, 86, 125-139.	0.6	27

#	ARTICLE	IF	CITATIONS
19	Imaging in Bladder Cancer: Present Role and Future Perspectives. <i>Urologia Internationalis</i> , 2010, 85, 373-380.	0.6	26
20	Social, economic, and health utility considerations in the treatment of overactive bladder. <i>Open Access Journal of Urology</i> , 0, , 11.	0.3	26
21	Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. <i>International Urogynecology Journal</i> , 2008, 19, 583-598.	0.7	25
22	Social, economic, and health utility considerations in the treatment of overactive bladder. <i>Research and Reports in Urology</i> , 2010, Volume 2, 11-24.	0.6	25
23	Is extracorporeal shock wave lithotripsy in pediatrics a safe procedure?. <i>Journal of Pediatric Surgery</i> , 2008, 43, 591-596.	0.8	24
24	Bladder pain syndrome associated with highest impact on sexual function among women with lower urinary tract symptoms. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 117, 168-172.	1.0	23
25	Artificial urinary sphincter significantly better than fixed sling for moderate post-prostatectomy stress urinary incontinence: a propensity score-matched study. <i>BJU International</i> , 2021, 127, 229-237.	1.3	23
26	Peyronie's Disease: Lights and Shadows. <i>Urologia Internationalis</i> , 2007, 78, 1-9.	0.6	21
27	Joint consensus on anesthesia in urologic and gynecologic robotic surgery: specific issues in management from a task force of the SIAARTI, SIGO, and SIU. <i>Minerva Anestesiologica</i> , 2019, 85, 871-885.	0.6	21
28	Thermochemotherapy for Non-Muscle-Invasive Bladder Cancer: Is There a Chance to Avoid Early Cystectomy?. <i>Urologia Internationalis</i> , 2012, 89, 311-318.	0.6	19
29	Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 315-324.	0.7	18
30	Patient pad count is a poor measure of urinary incontinence compared with 48-h pad test: results of a large-scale multicentre study. <i>BJU International</i> , 2019, 123, E69-E78.	1.3	18
31	KV7 channels in the human detrusor: channel modulator effects and gene and protein expression. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 127-137.	1.4	17
32	Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?. <i>International Urogynecology Journal</i> , 2015, 26, 629-640.	0.7	15
33	Titanized Transobturator Sling Placement for Male Stress Urinary Incontinence Using an Inside-out Single-incision Technique: Minimum 12-Months Follow-up Study. <i>Urology</i> , 2018, 115, 144-150.	0.5	15
34	Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 637-644.	0.9	15
35	Plasma Chromogranin A in Patients with Prostate Cancer Improves the Diagnostic Efficacy of Free/Total Prostate-Specific Antigen Determination. <i>Urologia Internationalis</i> , 2005, 75, 57-61.	0.6	14
36	^{99m} Tc-MAG3 Diuretic Renography in Diagnosis of Obstructive Nephropathy in Adults. <i>Clinical Nuclear Medicine</i> , 2013, 38, 432-436.	0.7	14

#	ARTICLE	IF	CITATIONS
37	Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 576-583.	2.6	14
38	How to Prevent Catheter-Associated Urinary Tract Infections: A Reappraisal of Vico's Theory's History Repeating Itself?. <i>Journal of Clinical Medicine</i> , 2022, 11, 3415.	1.0	13
39	Advanced bladder cancer: New agents and new approaches. A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 9-16.	0.8	12
40	The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration. <i>Cancer Cytopathology</i> , 2018, 126, 200-206.	1.4	12
41	Cancer and aging: The molecular pathways. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 620-627.	0.8	11
42	OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder neck dysfunction: Objective and patient-reported outcomes. <i>Neurourology and Urodynamics</i> , 2014, 33, 142-146.	0.8	11
43	The challenges of Bacillus of Calmette-Guerin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients. <i>Journal of Geriatric Oncology</i> , 2018, 9, 507-512.	0.5	11
44	Extensive impact of COVID-19 pandemic on pelvic floor dysfunctions care: A nationwide interdisciplinary survey. <i>Neurourology and Urodynamics</i> , 2021, 40, 695-704.	0.8	11
45	Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. <i>Human Pathology</i> , 2021, 118, 42-48.	1.1	11
46	Role of SOCS3 Evaluated by Immunohistochemical Analysis in a Cohort of Patients Affected by Prostate Cancer: Preliminary Results. <i>Urologia</i> , 2012, 79, 4-8.	0.3	10
47	High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives. <i>Scandinavian Journal of Urology</i> , 2013, 47, 179-187.	0.6	10
48	Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravesical hyperthermia and chemotherapy (thermochemotherapy). <i>Pathology Research and Practice</i> , 2017, 213, 1078-1081.	1.0	10
49	The combination cytology/epicheck test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 131.e17-131.e21.	0.8	10
50	Endourethral Migration of a Hem-o-Lok Clip after Robot-Assisted Laparoscopic Radical Prostatectomy. <i>Urologia</i> , 2015, 82, 242-244.	0.3	9
51	Cytological features of micropapillary and plasmacytoid variants of urothelial carcinoma. <i>Diagnostic Cytopathology</i> , 2020, 48, 111-117.	0.5	9
52	Bladder cancer in the time of machine learning: Intelligent tools for diagnosis and management. <i>Urologia</i> , 2021, 88, 94-102.	0.3	9
53	Improved Non-Invasive Diagnosis of Bladder Cancer with an Electronic Nose: A Large Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4984.	1.0	9
54	Lifestyle in urology: Cancer. <i>Urologia</i> , 2019, 86, 105-114.	0.3	8

#	ARTICLE	IF	CITATIONS
55	Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 214-222.	3.9	8
56	Size of Bladder Cancers: Correlation among Different Types of Measurement. <i>Urologia Internationalis</i> , 2013, 90, 191-194.	0.6	7
57	Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1989-1997.	0.9	7
58	Methylation study of the Paris system for reporting urinary (TPS) categories. <i>Journal of Clinical Pathology</i> , 2021, 74, 102-105.	1.0	7
59	Mirabegron, a novel, non-antimuscarinic drug for the overactive bladder: An up-to-dated review. <i>World Journal of Obstetrics and Gynecology</i> , 2013, 2, 65.	0.5	7
60	Intraprostatic botulinum toxin type A injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation. <i>Neurourology and Urodynamics</i> , 2018, 37, 1031-1038.	0.8	6
61	Objectively improving appropriateness of absorbent products provision to patients with urinary incontinence: The DIAPPER study. <i>Neurourology and Urodynamics</i> , 2018, 37, 485-495.	0.8	6
62	Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e100-e119.	0.9	6
63	Intensive Intravesical Mitomycin C Therapy in Non-Muscle-Invasive Bladder Cancer: A Dose Intensity Approach. <i>Urologia Internationalis</i> , 2010, 85, 266-269.	0.6	5
64	Paraneoplastic Dermatomyositis Associated With Panurothelial Transitional Cell Carcinoma: A Case Report and Literature Review. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e199-e201.	0.9	5
65	Multiparametric magnetic resonance imaging of the prostate: Lights and shadows. <i>Urologia</i> , 2021, 88, 280-286.	0.3	5
66	Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 209-223.	0.8	5
67	A multi-surgeon learning curve analysis of overall and site-specific positive surgical margins after RARP and implications for training. <i>Journal of Robotic Surgery</i> , 2022, , 1.	1.0	5
68	SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System. <i>Prostate</i> , 2017, 77, 597-603.	1.2	4
69	Germ Cell Neoplasia in situ (GCNIS) in Testis-Sparing Surgery (TSS) for Small Testicular Masses (STMs). <i>Frontiers in Endocrinology</i> , 2019, 10, 512.	1.5	4
70	Methodology of Superficial Bladder Cancer Trials: Objective Evaluation of Treatment – The Need for Standardization. <i>Urologia Internationalis</i> , 2009, 83, 258-263.	0.6	3
71	Microbiological follow-up of Nosocomial Infections in a Single Urological Center. <i>Urologia</i> , 2012, 79, 147-151.	0.3	3
72	Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review. <i>International Urogynecology Journal</i> , 2016, 27, 1633-1644.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Psychological aptitude for surgery: The importance of non-technical skills. <i>Urologia</i> , 2019, 86, 45-51.	0.3	3
74	34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 306-310.	0.6	3
75	Rate of clinically significant prostate cancer on repeat saturation biopsy after a diagnosis of atypical small acinar proliferation. <i>Urologia</i> , 2021, 88, 194-199.	0.3	3
76	Pioneering drugs for overactive bladder and detrusor overactivity: Ongoing research and future directions. <i>World Journal of Obstetrics and Gynecology</i> , 2015, 4, 24.	0.5	3
77	InTrathecal mORphine, traNsversus Abdominis Plane Block, and tramaDOI Infusion for Catheter-Related Bladder Discomfort in Patients Undergoing Robot-Assisted Laparoscopic Prostatectomy (TORNADO): A Pilot Prospective Controlled Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2136.	1.0	3
78	High intensity focused ultrasound as first line salvage therapy in prostate cancer local relapse after radical prostatectomy: 4-year follow-up outcomes. <i>Minerva Urology and Nephrology</i> , 2016, 69, 93-100.	1.3	2
79	Paraneoplastic Hyperinsulinism due to Renal Cell Carcinoma Treated With Robotic Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e107-e109.	0.9	2
80	Management of Iatrogenic Bladder Injury due to Vascular Surgery: Case Report and Literature Review. <i>Annals of Vascular Surgery</i> , 2019, 59, 307.e13-307.e16.	0.4	2
81	In vitro Effect of Amikacin on Rat and Human Detrusor Muscle Contraction. <i>Urologia Internationalis</i> , 2008, 81, 94-100.	0.6	1
82	Lifestyle in urology: Benign diseases. <i>Urologia</i> , 2021, 88, 163-174.	0.3	1
83	Male sling placement for post-prostatectomy incontinence can involve a lengthy learning curve: A multi-outcome assessment via cumulative sum failure analysis. <i>Urologia</i> , 2022, 89, 521-528.	0.3	1
84	Inhibition of prostate efferent neurotransmission by amikacin. <i>Prostate</i> , 2008, 68, 1330-1335.	1.2	0
85	Continuing evolution of statistical tests in medical research. <i>Urologia</i> , 2010, 77, 232-239.	0.3	0
86	The Occult Urothelial Cancer. <i>Urologia</i> , 2016, 83, 55-60.	0.3	0
87	Renal effect of severe hypoxia evaluated By NGAL measurements: An in vivo and in vitro study. <i>Urologia</i> , 2022, 89, 38-43.	0.3	0
88	Comments on a case of ureteropelvic junction obstruction with late progression in an adult female. <i>Urologia</i> , 2021, 88, 247-250.	0.3	0